Abstract
Background: Risk factors for developing long COVID are not clearly established. The present study was designed to determine if any sign, symptom, or treatment of the acute phase, or personal characteristics of the patient, is associated with the development of long COVID. Methods: A cohort study was carried out, randomly selecting symptomatic COVID-19 patients and not vaccinated. The severity of the acute illness was assessed through the number of compatible COVID-19 symptoms, hospitalizations, and the symptom severity score using a 10-point visual analog scale. Results: After multivariate analysis, a severity score ≥8 (RR 2.0, 95%CI 1.1–3.5, p = 0.022), hospitalization (RR 2.1, 95%CI 1.0–4.4, p = 0.039), myalgia (RR 1.9, 95%CI 1.08–3.6, p = 0.027), tachycardia (RR 10.4, 95%CI 2.2–47.7, p = 0.003), and use of antibiotics (RR 2.0, 95%CI 1.1–3.5, p = 0.022), was positively associated with the risk of having long COVID. Higher levels of education (RR 0.6, 95%CI 0.4–0.9, p = 0.029) and type positive B blood group (B + AB, RR 0.44, 95%CI 0.2–0.9, p = 0.044) were protective factors. The most important population attributable fractions (PAFs) for long COVID were myalgia (37%), severity score ≥8 (31%), and use of antibiotics (27%). Conclusions: Further studies in diverse populations over time are needed to expand the knowledge that could lead us to prevent and/or treat long COVID.
Funder
Consejo Nacional de Ciencia y Tecnología
Subject
Health Information Management,Health Informatics,Health Policy,Leadership and Management
Reference43 articles.
1. Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., and Di Napoli, R. (2020). Treasure Island (FL), StatPearls Publishing.
2. The Coronavirus Disease (COVID-19) Challenge in Mexico: A Critical and Forced Reflection as Individuals and Society;Front. Public Heal.,2020
3. Safety and Efficacy of a COVID-19 Treatment with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care vs. Usual Medical Care Alone: A Randomized, Open-label, Controlled Trial;Exp. Ther. Med.,2021
4. Abdelhafiz, A.S., Ali, A., Maaly, A.M., Mahgoub, M.A., Ziady, H.H., and Sultan, E.A. (2022). Predictors of Post-COVID Symptoms in Egyptian Patients: Drugs Used in COVID-19 Treatment Are Incriminated. PLoS ONE, 17.
5. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022;Havers;JAMA Intern. Med.,2022